

Rocchina Lucia Colucci

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3637550/publications.pdf>

Version: 2024-02-01

113
papers

4,316
citations

81743

39
h-index

149479

56
g-index

114
all docs

114
docs citations

114
times ranked

5599
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | The role of serotonin and its pathways in gastrointestinal disorders. , 2021, , 67-94. | | 1 |
| 2 | Preclinical Development of FA5, a Novel AMP-Activated Protein Kinase (AMPK) Activator as an Innovative Drug for the Management of Bowel Inflammation. International Journal of Molecular Sciences, 2021, 22, 6325. | 1.8 | 5 |
| 3 | NLRP3 at the crossroads between immune/inflammatory responses and enteric neuroplastic remodelling in a mouse model of diet-induced obesity. British Journal of Pharmacology, 2021, 178, 3924-3942. | 2.7 | 9 |
| 4 | Protective effects of the combination Bifidobacterium longum plus lactoferrin against NSAID-induced enteropathy. Nutrition, 2020, 70, 110583. | 1.1 | 16 |
| 5 | Prodromal Intestinal Events in Alzheimer's Disease (AD): Colonic Dysmotility and Inflammation Are Associated with Enteric AD-Related Protein Deposition. International Journal of Molecular Sciences, 2020, 21, 3523. | 1.8 | 24 |
| 6 | Microbiota-gut-brain axis in health and disease: Is NLRP3 inflammasome at the crossroads of microbiota-gut-brain communications?. Progress in Neurobiology, 2020, 191, 101806. | 2.8 | 87 |
| 7 | Role of proteinase-activated receptors 1 and 2 in nonsteroidal anti-inflammatory drug enteropathy. Pharmacological Reports, 2020, 72, 1347-1357. | 1.5 | 4 |
| 8 | Pathological remodelling of colonic wall following dopaminergic nigrostriatal neurodegeneration. Neurobiology of Disease, 2020, 139, 104821. | 2.1 | 28 |
| 9 | Colonic dysmotility associated with high-fat diet-induced obesity: Role of enteric glia. FASEB Journal, 2020, 34, 5512-5524. | 0.2 | 31 |
| 10 | Glial A2B Adenosine Receptors Modulate Abnormal Tachykininergic Responses and Prevent Enteric Inflammation Associated with High Fat Diet-Induced Obesity. Cells, 2020, 9, 1245. | 1.8 | 20 |
| 11 | Intestinal epithelial barrier and neuromuscular compartment in health and disease. World Journal of Gastroenterology, 2020, 26, 1564-1597. | 1.4 | 28 |
| 12 | Interplay between colonic inflammation and tachykininergic pathways in the onset of colonic dysmotility in a mouse model of diet-induced obesity. International Journal of Obesity, 2019, 43, 331-343. | 1.6 | 27 |
| 13 | Microvascular Endothelial Dysfunction in Patients with Obesity. Current Hypertension Reports, 2019, 21, 32. | 1.5 | 53 |
| 14 | Microvascular Endothelial Dysfunction in Human Obesity: Role of TNF- α . Journal of Clinical Endocrinology and Metabolism, 2019, 104, 341-348. | 1.8 | 54 |
| 15 | Anti-inflammatory effect of a novel locally acting A2A receptor agonist in a rat model of oxazolone-induced colitis. Purinergic Signalling, 2018, 14, 27-36. | 1.1 | 19 |
| 16 | Pathophysiology of NSAID-Associated Intestinal Lesions in the Rat: Luminal Bacteria and Mucosal Inflammation as Targets for Prevention. Frontiers in Pharmacology, 2018, 9, 1340. | 1.6 | 35 |
| 17 | A Comparative Study on the Efficacy of NLRP3 Inflammasome Signaling Inhibitors in a Pre-clinical Model of Bowel Inflammation. Frontiers in Pharmacology, 2018, 9, 1405. | 1.6 | 33 |
| 18 | The ecto-enzymes CD73 and adenosine deaminase modulate 5 α -AMP-derived adenosine in myofibroblasts of the rat small intestine. Purinergic Signalling, 2018, 14, 409-421. | 1.1 | 11 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Aging Modulates the Influence of Arginase on Endothelial Dysfunction in Obesity. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 2474-2483. | 1.1 | 41 |
| 20 | Luteolin Prevents Cardiometabolic Alterations and Vascular Dysfunction in Mice With HFD-Induced Obesity. <i>Frontiers in Pharmacology</i> , 2018, 9, 1094. | 1.6 | 46 |
| 21 | Interplay among gut microbiota, intestinal mucosal barrier and enteric neuro-immune system: a common path to neurodegenerative diseases?. <i>Acta Neuropathologica</i> , 2018, 136, 345-361. | 3.9 | 167 |
| 22 | The flavonoid compound apigenin prevents colonic inflammation and motor dysfunctions associated with high fat diet-induced obesity. <i>PLoS ONE</i> , 2018, 13, e0195502. | 1.1 | 47 |
| 23 | Dietary flavonoids as a potential intervention to improve redox balance in obesity and related co-morbidities: a review. <i>Nutrition Research Reviews</i> , 2018, 31, 239-247. | 2.1 | 40 |
| 24 | Colonic Dysmotility Associated with High Fat Diet-Induced Obesity: Role of the Enteric Glia. <i>Gastroenterology</i> , 2017, 152, S180. | 0.6 | 1 |
| 25 | Effects of L-DOPA/benserazide co-treatment on colonic excitatory cholinergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration. <i>Neuropharmacology</i> , 2017, 123, 22-33. | 2.0 | 15 |
| 26 | Colonic motor dysfunctions in a mouse model of high-fat diet-induced obesity: an involvement of A2B adenosine receptors. <i>Purinergic Signalling</i> , 2017, 13, 497-510. | 1.1 | 30 |
| 27 | Intestinal dysfunction in Parkinson's disease: Lessons learned from translational studies and experimental models. <i>Neurogastroenterology and Motility</i> , 2016, 28, 1781-1791. | 1.6 | 41 |
| 28 | Alteration of colonic excitatory tachykininergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration. <i>Journal of Neuroinflammation</i> , 2016, 13, 146. | 3.1 | 77 |
| 29 | Fibrotic and Vascular Remodelling of Colonic Wall in Patients with Active Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 1194-1204. | 0.6 | 50 |
| 30 | Enteric Dysfunctions in Experimental Parkinsons Disease: Alterations of Excitatory Cholinergic Neurotransmission Regulating Colonic Motility in Rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2016, 356, 233-243. | 1.3 | 49 |
| 31 | Small bowel protection against NSAID-injury in rats: Effect of rifaximin, a poorly absorbed, GI targeted, antibiotic. <i>Pharmacological Research</i> , 2016, 104, 186-196. | 3.1 | 30 |
| 32 | The AMPK enzyme-complex: from the regulation of cellular energy homeostasis to a possible new molecular target in the management of chronic inflammatory disorders. <i>Expert Opinion on Therapeutic Targets</i> , 2016, 20, 179-191. | 1.5 | 41 |
| 33 | An integrated assessment of histopathological changes of the enteric neuromuscular compartment in experimental colitis. <i>Journal of Cellular and Molecular Medicine</i> , 2015, 19, 485-500. | 1.6 | 29 |
| 34 | Genetics and pharmacogenetics of aminergic transmitter pathways in functional gastrointestinal disorders. <i>Pharmacogenomics</i> , 2015, 16, 523-539. | 0.6 | 13 |
| 35 | Chrelin restores nitric oxide availability in resistance circulation of essential hypertensive patients: role of NAD(P)H oxidase. <i>European Heart Journal</i> , 2015, 36, ehv365. | 1.0 | 30 |
| 36 | Gastric motor dysfunctions in Parkinson's disease: Current pre-clinical evidence. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1407-1414. | 1.1 | 56 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Exploring the genetics of irritable bowel syndrome: a GWA study in the general population and replication in multinational case-control cohorts. <i>Gut</i> , 2015, 64, 1774-1782. | 6.1 | 97 |
| 38 | Involvement of the P2X7 Purinergic Receptor in Colonic Motor Dysfunction Associated with Bowel Inflammation in Rats. <i>PLoS ONE</i> , 2014, 9, e116253. | 1.1 | 41 |
| 39 | Role of the α_2B receptor-adenosine deaminase complex in colonic dysmotility associated with bowel inflammation in rats. <i>British Journal of Pharmacology</i> , 2014, 171, 1314-1329. | 2.7 | 26 |
| 40 | Role of cyclooxygenase isoforms in the altered excitatory motor pathways of human colon with diverticular disease. <i>British Journal of Pharmacology</i> , 2014, 171, 3728-3740. | 2.7 | 10 |
| 41 | Adenosine and inflammation: what's new on the horizon?. <i>Drug Discovery Today</i> , 2014, 19, 1051-1068. | 3.2 | 139 |
| 42 | Adenosine pathway and cancer: where do we go from here?. <i>Expert Opinion on Therapeutic Targets</i> , 2014, 18, 973-977. | 1.5 | 16 |
| 43 | NSAID-Induced Enteropathy: Are the Currently Available Selective COX-2 Inhibitors All the Same?. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2014, 348, 86-95. | 1.3 | 44 |
| 44 | The role of purinergic pathways in the pathophysiology of gut diseases: Pharmacological modulation and potential therapeutic applications. , 2013, 139, 157-188. | | 60 |
| 45 | Response to Endothelial Nitric Oxide Synthase, Cyclooxygenase-2, and Essential Hypertension: Is There an Interaction?. <i>Hypertension</i> , 2013, 62, e16. | 1.3 | 1 |
| 46 | Rosuvastatin prevents angiotensin II-induced vascular changes by inhibition of NAD(P)H oxidase and COX-1. <i>British Journal of Pharmacology</i> , 2013, 169, 554-566. | 2.7 | 18 |
| 47 | Endothelial Dysfunction in Small Arteries of Essential Hypertensive Patients. <i>Hypertension</i> , 2013, 62, 337-344. | 1.3 | 97 |
| 48 | Altered Expression Pattern of Molecular Factors Involved in Colonic Smooth Muscle Functions: An Immunohistochemical Study in Patients with Diverticular Disease. <i>PLoS ONE</i> , 2013, 8, e57023. | 1.1 | 28 |
| 49 | Influence of the Serotonin Transporter 5HTTLPR Polymorphism on Symptom Severity in Irritable Bowel Syndrome. <i>PLoS ONE</i> , 2013, 8, e54831. | 1.1 | 37 |
| 50 | Nonsteroidal Anti-Inflammatory Drug-Activated Gene-1 Plays a Role in the Impairing Effects of Cyclooxygenase Inhibitors on Gastric Ulcer Healing. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2012, 342, 140-149. | 1.3 | 14 |
| 51 | Resistance artery mechanics and composition in angiotensin II-infused mice: effects of cyclooxygenase-1 inhibition. <i>European Heart Journal</i> , 2012, 33, 2225-2234. | 1.0 | 28 |
| 52 | Adenosine Deaminase in the Modulation of Immune System and its Potential as a Novel Target for Treatment of Inflammatory Disorders. <i>Current Drug Targets</i> , 2012, 13, 842-862. | 1.0 | 128 |
| 53 | 15 Altered Adenosine Signalling in the Presence of Bowel Inflammation: Role of α_2B Receptors in the Control of Colonic Motility. <i>Gastroenterology</i> , 2012, 142, S-4. | 0.6 | 1 |
| 54 | Immunohistochemical analysis of myenteric ganglia and interstitial cells of Cajal in ulcerative colitis. <i>Journal of Cellular and Molecular Medicine</i> , 2012, 16, 318-327. | 1.6 | 88 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Vascular Generation of Tumor Necrosis Factor- α Reduces Nitric Oxide Availability in Small Arteries From Visceral Fat of Obese Patients. <i>Journal of the American College of Cardiology</i> , 2011, 58, 238-247. | 1.2 | 98 |
| 56 | Effects of esomeprazole on healing of nonsteroidal anti-inflammatory drug (NSAID)-induced gastric ulcers in the presence of a continued NSAID treatment: Characterization of molecular mechanisms. <i>Pharmacological Research</i> , 2011, 63, 59-67. | 3.1 | 34 |
| 57 | A holistic view of adenosine in the control of intestinal neuromuscular functions: the enteric "purinome" concept. <i>British Journal of Pharmacology</i> , 2011, 164, 1577-1579. | 2.7 | 10 |
| 58 | Differential recruitment of high affinity A ₁ and A _{2A} adenosine receptors in the control of colonic neuromuscular function in experimental colitis. <i>European Journal of Pharmacology</i> , 2011, 650, 639-649. | 1.7 | 41 |
| 59 | Derivatives of Benzimidazolquinoline and Benzimidazolisoquinoline as Selective A ₁ Adenosine Receptor Antagonists with Stimulant Activity on Human Colon Motility. <i>ChemMedChem</i> , 2011, 6, 1909-1918. | 1.6 | 16 |
| 60 | Pharmacological modulation of adenosine receptor pathways and inflammatory disorders: the way towards novel therapeutics?. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 717-721. | 1.9 | 4 |
| 61 | Emerging role of cyclooxygenase isoforms in the control of gastrointestinal neuromuscular functions. , 2010, 125, 62-78. | | 27 |
| 62 | Control of enteric neuromuscular functions by purinergic A ₃ receptors in normal rat distal colon and experimental bowel inflammation. <i>British Journal of Pharmacology</i> , 2010, 161, 856-871. | 2.7 | 29 |
| 63 | The Blockade of Adenosine Deaminase Ameliorates Chronic Experimental Colitis through the Recruitment of Adenosine A _{2A} and A ₃ Receptors. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2010, 335, 434-442. | 1.3 | 47 |
| 64 | Use of Selective Serotonin Reuptake Inhibitors during Pregnancy and Risk of Major and Cardiovascular Malformations: An Update. <i>Postgraduate Medicine</i> , 2010, 122, 49-65. | 0.9 | 34 |
| 65 | Atorvastatin Prevents Endothelial Dysfunction in Mesenteric Arteries From Spontaneously Hypertensive Rats. <i>Hypertension</i> , 2009, 53, 1008-1016. | 1.3 | 62 |
| 66 | Inducible Nitric Oxide Synthase Is Involved in Endothelial Dysfunction of Mesenteric Small Arteries from Hypothyroid Rats. <i>Endocrinology</i> , 2009, 150, 1033-1042. | 1.4 | 33 |
| 67 | Safety concerns associated with the use of serotonin reuptake inhibitors and other serotonergic/noradrenergic antidepressants during pregnancy: A review. <i>Clinical Therapeutics</i> , 2009, 31, 1426-1453. | 1.1 | 92 |
| 68 | Effects of pantoprazole on ulcer healing delay associated with NSAID treatment. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2009, 379, 305-313. | 1.4 | 5 |
| 69 | A ₁ and A _{2a} receptors mediate inhibitory effects of adenosine on the motor activity of human colon. <i>Neurogastroenterology and Motility</i> , 2009, 21, 451-466. | 1.6 | 24 |
| 70 | Characterization of mechanisms underlying the effects of esomeprazole on the impairment of gastric ulcer healing with addition of NSAID treatment. <i>Digestive and Liver Disease</i> , 2009, 41, 395-405. | 0.4 | 26 |
| 71 | Role of coxibs in the strategies for gastrointestinal protection in patients requiring chronic non-steroidal anti-inflammatory therapy. <i>Pharmacological Research</i> , 2009, 59, 90-100. | 3.1 | 40 |
| 72 | Pharmacological modulation of adenosine system: Novel options for treatment of inflammatory bowel diseases. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 566-574. | 0.9 | 57 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Somatostatin inhibits colon cancer cell growth through cyclooxygenase-2 downregulation. <i>British Journal of Pharmacology</i> , 2008, 155, 198-209. | 2.7 | 31 |
| 74 | The β_3 -adrenoceptor agonist SR58611A ameliorates experimental colitis in rats. <i>Neurogastroenterology and Motility</i> , 2008, 20, 1030-1041. | 1.6 | 44 |
| 75 | Review article: molecular, pathological and therapeutic features of human enteric neuropathies. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 28, 25-42. | 1.9 | 111 |
| 76 | Regulation of enteric functions by adenosine: Pathophysiological and pharmacological implications. , 2008, 120, 233-253. | | 103 |
| 77 | Clinical Efficacy of Esomeprazole in the Prevention and Healing of Gastrointestinal Toxicity Associated with NSAIDs in Elderly Patients. <i>Drugs and Aging</i> , 2008, 25, 197-208. | 1.3 | 23 |
| 78 | The genetics of the serotonin transporter and irritable bowel syndrome. <i>Trends in Molecular Medicine</i> , 2008, 14, 295-304. | 3.5 | 43 |
| 79 | Effects of a bicarbonate-alkaline mineral water on digestive motility in experimental models of functional and inflammatory gastrointestinal disorders. <i>Methods and Findings in Experimental and Clinical Pharmacology</i> , 2008, 30, 261. | 0.8 | 10 |
| 80 | Cyclooxygenase-1 Is Involved in Endothelial Dysfunction of Mesenteric Small Arteries From Angiotensin II-Infused Mice. <i>Hypertension</i> , 2007, 49, 679-686. | 1.3 | 66 |
| 81 | Inhibition of Adenosine Deaminase Attenuates Inflammation in Experimental Colitis. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 322, 435-442. | 1.3 | 96 |
| 82 | Cholecystokinin CCK2 receptors mediate the peptide's inhibitory actions on the contractile activity of human distal colon via the nitric oxide pathway. <i>British Journal of Pharmacology</i> , 2007, 151, 1246-1253. | 2.7 | 13 |
| 83 | CCK2 receptors mediate inhibitory effects of cholecystokinin on the motor activity of guinea-pig distal colon. <i>European Journal of Pharmacology</i> , 2007, 557, 212-220. | 1.7 | 9 |
| 84 | Cyclooxygenase-2 Induction after Oral Surgery Does Not Entirely Account for Analgesia after Selective Blockade of Cyclooxygenase 2 in the Preoperative Period. <i>Anesthesiology</i> , 2006, 104, 152-157. | 1.3 | 6 |
| 85 | Constitutive expression of cyclooxygenase-2 in the neuromuscular compartment of normal human colon. <i>Neurogastroenterology and Motility</i> , 2006, 18, 654-662. | 1.6 | 25 |
| 86 | A2a receptors mediate inhibitory effects of adenosine on colonic motility in the presence of experimental colitis. <i>Inflammatory Bowel Diseases</i> , 2006, 12, 117-122. | 0.9 | 39 |
| 87 | Differential Role of Cyclooxygenase 1 and 2 Isoforms in the Modulation of Colonic Neuromuscular Function in Experimental Inflammation. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 317, 938-945. | 1.3 | 34 |
| 88 | Gastrin promotes human colon cancer cell growth via CCK-2 receptor-mediated cyclooxygenase-2 induction and prostaglandin E2 production. <i>British Journal of Pharmacology</i> , 2005, 144, 338-348. | 2.7 | 59 |
| 89 | Mechanisms of protection by pantoprazole against NSAID-induced gastric mucosal damage. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2005, 372, 79-87. | 1.4 | 45 |
| 90 | Role of cyclooxygenases 1 and 2 in the modulation of neuromuscular functions in the distal colon of humans and mice. <i>Gut</i> , 2005, 54, 608-616. | 6.1 | 52 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | Cyclooxygenase-2 Inhibition Improves Vascular Endothelial Dysfunction in a Rat Model of Endotoxic Shock: Role of Inducible Nitric-Oxide Synthase and Oxidative Stress. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 312, 945-953. | 1.3 | 92 |
| 92 | Clinical evaluation of piroxicam-FDDF and azithromycin in the prevention of complications associated with impacted lower third molar extraction. <i>Pharmacological Research</i> , 2005, 52, 485-490. | 3.1 | 26 |
| 93 | Lansoprazole prevents experimental gastric injury induced by non-steroidal anti-inflammatory drugs through a reduction of mucosal oxidative damage. <i>World Journal of Gastroenterology</i> , 2005, 11, 4052. | 1.4 | 61 |
| 94 | Mechanisms of gastroprotection by lansoprazole pretreatment against experimentally induced injury in rats: role of mucosal oxidative damage and sulfhydryl compounds. <i>Toxicology and Applied Pharmacology</i> , 2004, 195, 62-72. | 1.3 | 57 |
| 95 | Altered prejunctional modulation of intestinal cholinergic and noradrenergic pathways by $\hat{1}\pm 2$ -adrenoceptors in the presence of experimental colitis. <i>British Journal of Pharmacology</i> , 2003, 139, 309-320. | 2.7 | 74 |
| 96 | Platelet Serotonin Transporter in Patients With Diarrhea-Predominant Irritable Bowel Syndrome Both Before and After Treatment With Alosetron. <i>American Journal of Gastroenterology</i> , 2003, 98, 2705-2711. | 0.2 | 53 |
| 97 | Efficacy and Tolerability of Meloxicam, a COX-2 Preferential Nonsteroidal Anti-Inflammatory Drug. <i>Clinical Drug Investigation</i> , 2002, 22, 799-818. | 1.1 | 52 |
| 98 | Cholinergic toxic syndrome by the anticancer drug irinotecan: Acetylcholinesterase does not play a major role. <i>Clinical Pharmacology and Therapeutics</i> , 2002, 71, 263-271. | 2.3 | 6 |
| 99 | H 3 receptor-mediated inhibition of intestinal acetylcholine release: pharmacological characterization of signal transduction pathways. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2001, 363, 193-202. | 1.4 | 15 |
| 100 | Acetylcholinesterase Blockade Does Not Account for the Adverse Cardiovascular Effects of the Antitumor Drug Irinotecan: A Preclinical Study. <i>Toxicology and Applied Pharmacology</i> , 2001, 177, 149-156. | 1.3 | 8 |
| 101 | Characterization of a novel mechanism accounting for the adverse cholinergic effects of the anticancer drug irinotecan. <i>British Journal of Pharmacology</i> , 2001, 132, 73-84. | 2.7 | 28 |
| 102 | Histamine H3 receptors mediate inhibition of noradrenaline release from intestinal sympathetic nerves. <i>British Journal of Pharmacology</i> , 2000, 129, 1387-1396. | 2.7 | 29 |
| 103 | Gastroprotective effects of pantoprazole against experimental mucosal damage. <i>Fundamental and Clinical Pharmacology</i> , 2000, 14, 89-99. | 1.0 | 17 |
| 104 | Acid-independent gastroprotective effects of lansoprazole in experimental mucosal injury. <i>Digestive Diseases and Sciences</i> , 1999, 44, 2039-2050. | 1.1 | 37 |
| 105 | CCK1 and CCK2 receptors regulate gastric pepsinogen secretion. <i>European Journal of Pharmacology</i> , 1999, 373, 71-84. | 1.7 | 13 |
| 106 | Effects of imidazoline derivatives on cholinergic motility in guinea-pig ileum: involvement of presynaptic $\hat{1}\pm 2$ -adrenoceptors or imidazoline receptors?. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1998, 357, 682-691. | 1.4 | 29 |
| 107 | Suramin enhances ethanol-induced injury to gastric mucosa in rats. <i>Digestive Diseases and Sciences</i> , 1997, 42, 1233-1241. | 1.1 | 8 |
| 108 | Determination on functional basis of presynaptic $\hat{1}\pm 2$ -adrenoceptor subtypes in guinea-pig duodenum. <i>Neuroscience Letters</i> , 1996, 210, 29-32. | 1.0 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | Central GABA-A receptors exert a tonic inhibitory control on gastric pepsinogen secretion in anaesthetized rats. <i>Autonomic and Autacoid Pharmacology</i> , 1995, 15, 187-196. | 0.7 | 1 |
| 110 | Central administration of cholecystokinin stimulates gastric pepsinogen secretion from anaesthetized rats. <i>Neuroscience Letters</i> , 1995, 193, 13-16. | 1.0 | 3 |
| 111 | Characterization of β_2 -adrenoceptor subtypes involved in the modulation of gastric acid secretion. <i>European Journal of Pharmacology</i> , 1995, 278, 179-182. | 1.7 | 23 |
| 112 | Role of peripheral GABAB receptors in the regulation of pepsinogen secretion in anaesthetized rats. <i>European Journal of Pharmacology</i> , 1995, 294, 191-200. | 1.7 | 13 |
| 113 | Pathophysiology of Gastric Ulcer Development and Healing: Molecular Mechanisms and Novel Therapeutic Options. , 0, , . | | 18 |